JNK

<p>Mefloquine hydrochloride (Mefloquin hydrochloride) is a quinoline derivative used for the prevention and therapy of P. falciparum malaria.</p>

<p>Tanzisertib (CC-930) (CC-930) is a potent inhibitor of JNK1/2/3 with IC50s of 61/7/6 nM, respectively, with potential antifibrotic activity.</p>

<p>SU3327 (halicin) is a potent, selective and substrate-competitive inhibitor of JNK(IC50 of 0.7 μM).</p>

<p>NBDHEX is a potent inhibitor of glutathione S-transferase P1-1 (GSTP1-1).</p>

<p>JNK-IN-13 is a JNK inhibitor that inhibits JNK3 and JNK2 and can be used in the study of diabetes, inflammation, and neurological disorders.</p>

<p>Metacetamol, a non-toxic acetaminophen derivative, is an OTC analgesic/antipyretic and synthesis intermediate.</p>

<p>Mefloquine (Ro 215998), a quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor.</p>

<p>Chloramphenicol (Chloromycetin) is a broad-spectrum antibiotic that inhibits the biosynthesis of bacterial proteins. Cost-effective and quality-assured.</p>

<p>Urolithin B is one of the gut microbial metabolites of ellagitannins and is found in diverse plant foods, including pomegranates, berries, walnuts, tropical</p>

<p>Fasudil (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK.</p>

<p>JNK-1-IN-3 (Compound 9e) downregulates JNK1 and phosphorylated JNK1, reduces c-Jun and c-Fos expression in tumours, and restores p53 activity.</p>

<p>OVA-E1 peptide TFA activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes.</p>

<p>SP 600125, negative control is a methylated analog of SP 600125 and can be used as a negative control for SP 600125.</p>

<p>JNK-IN-18 (compound 23b) is a potent inhibitor of JNK1, boasting an IC50 of 2 nM. It demonstrates superior efficacy when compared to its IC50 values of 125 nM for JNK2 and 98 nM for BRAF(V600E).</p>

<p>A unique collection of 365 compounds targeting MAPK signaling for drug discovery in MAPK related diseases;</p>

<p>D-JBD19 is a non-permeable peptide with neuroprotective effects.</p>

<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>

<p>JNK-IN-12 (compound P2) is a mitochondrial-targeted JNK inhibitor with an IC50 value of 66.3 nM, comprising a mitochondrial-specific cell-penetrating peptide</p>

<p>MAP4K4-IN-6 (Compound 15f) is a MAP4K4 inhibitor with an IC50 of 80 nM. It reduces the phosphorylation of c-Jun and exhibits neuroprotective effects. Additionally, MAP4K4-IN-6 enhances the vitality of motor neurons and can be utilized in the study of amyotrophic lateral sclerosis (ALS).</p>

<p>CC-401 is a specific inhibitor of JNK (Ki: 25-50nM).</p>

<p>N-Butyl α-D-fructofuranoside, extracted from the root barks of Ulmus davidiana var.</p>

<p>BRAFV600E/JNK-IN-1 (Compound 14c) is an inhibitor of JNK1, JNK2, JNK3, and BRAFV600E, with IC50 values of 0.51 μM, 0.53 μM, 1.02 μM, and 0.009 μM, respectively. It also inhibits the phosphorylation of MEK1/2 and ERK1/2. Additionally, BRAFV600E/JNK-IN-1 suppresses tumor cell proliferation, NO release, and PGE2 production, exhibiting both antitumor and anti-inflammatory activities.</p>

L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK, it has been shown to effectively inhibit JNK activity in in vivo studies.

<p>JNK2-IN-1 (Compound J27), a selective JNK2 inhibitor with a dissociation constant (Kd) of 79.2 µM, exhibits anti-inflammatory effects by attenuating TNF-α and</p>

<p>JNK3 inhibitor-8: potent, selective, oral, BBB-penetrating, IC50: JNK3=21 nM, JNK2=2203 nM, JNK1&gt;10,000 nM; potential in Alzheimer's research.</p>

<p>"JNK-1-IN-2 (Compound c6) is a potent inhibitor of JNK-1 with an IC50 of 33.5 nM, and also exhibits inhibitory effects on JNK-2 and JNK-3 with IC50 values of</p>

AS601245.2TFA (345987-15-7 free base) (AS601245.2TFA) is a cell-permeable Inhibitor of JNK (IC50s of 150, 220, and 70 nM for hJNK1, hJNK2, and hJNK3,

<p>JNK-IN-14 is a potent inhibitor of JNK with IC50 values of 1.81 nM for JNK1, 12.7 nM for JNK2, and 10.5 nM for JNK3.</p>

<p>Potent, oral JNK3 inhibitor-7 crosses blood-brain barrier, IC50: 53 nM (JNK3), offers neuroprotection, potential in AD research.</p>

<p>IQ-1S is an inhibitor of NF-κB/activating protein 1 (AP-1) with an IC50 of 1.8 μM. It exhibits high binding affinity to all three JNKs, with Kd values for JNK3, JNK2, and JNK1 being 87 nM, 360 nM, and 390 nM, respectively.</p>

<p>Vacquinol-1 is an MKK4 activator, which rapidly and selectively induces glioma cell death.</p>

<p>Peptide based on JIP-1(153-163) inhibits JNK with micromolar affinity; barely affects p38, ERK.</p>

<p>OVA-E1 peptide, as SIINFEKL variant, triggers similar p38/JNK activation in mutant and normal thymocytes.</p>

<p>PROTAC JNK1-targeted-1 (PA2) is a JNK1 PROTAC degrader with a DC50 of 10 nM. It effectively reduces fibronectin levels and is useful in lung fibrosis research. [Pink: JNK1 inhibitor; Black: linker; Blue: CRBN Ligand]</p>

<p>Ezatiostat (TER199(free base)) is a tripeptide analog of glutathione that can selectively inhibit GSTP1-1 catalytic activity.</p>

<p>Mitogen-activated protein kinase 8 (MAPK8), also known as JNK1, is a member of the MAP kinase family.</p>

<p>WHI-P258, a weak JAK3 inhibitor, is used as a negative control in drug development.</p>

<p>IMM-H007 is a novel lipid-lowering agent, increasing abca1 protein expression</p>

<p>AS601245 is an inhibitor of the c-Jun NH2-terminal kinase (JNK), with neuroprotective properties.</p>

<p>JNK Inhibitor VIII (TCS JNK 6o) is an ATP-competitive selective inhibitor of c-Jun N-terminal kinase (JNK)(IC50 values of 45 nM and 160 nM for JNK-1 and -2,</p>

<p>Taurochenodeoxycholic Acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid.</p>

<p>DB07268 is a potent and selective JNK1 inhibitor.</p>

<p>SP600125 (JNK Inhibitor II) is a JNK inhibitor that inhibits JNK1, JNK2, and JNK3 (IC50=40/40/90 nM) with oral potency, reversibility, and ATP-competitive</p>

<p>BI-78D3, a competitive JNK inhibitor. IC50 of BI-78D3 is 280 nM that displays &gt; 100 fold selectivity over p38α, and have no activity at mTOR and PI-3K.</p>

<p>Anisomycin (NSC-76712), an antibiotic from Streptomyces, blocks protein/DNA synthesis by targeting peptidyl transferase/80S ribosomes.</p>

<p>Loureirin B suppresses fibrosis by modulating MMPs/TIMPs, hindering fibroblast growth, and targeting TGF-β1/Smad2/3 pathway.</p>

<p>Tomatidine hydrochloride (Tomatidine HCl) is a steriodal alkaloid structurally similar to Cyclopamine but does not inhibit hedgehog pathway.</p>

<p>Actein stimulates bone formation, counters osteoporosis and oxidative damage, and may treat lipid disorders and cancer, inhibiting breast cancer cell growth.</p>

<p>Polyphyllin D induces apoptosis via the mitochondrial apoptotic pathway as evidenced by decreased Bcl-2 expression levels, disruption of MMP and increased Bax,</p>

<p>Ro 31-8220 Mesylate (Bisindolylmaleimide IX mesylate) is a pan-PKC inhibitor, and also shows potent inhibition against MSK1, MAPKAP-K1b, S6K1, and GSK3β.</p>

<p>Guggulsterone (Guggulsterone E&amp;Z) E&amp;Z is a 3-hydroxy steroid. It has a role as an androgen.</p>

<p>JNK-IN-7 (JNK inhibitor) is a selective JNK1/2/3 inhibitor (IC50: 1.54/1.99/0.75 nM).</p>

<p>CC-401 Hydrochloride (CC401 HCl) is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with antineoplastic activity.</p>

<p>Bentamapimod (AS 602801) is a novel, orally active inhibitor of JNK.</p>

<p>Astragaloside IV suppresses ERK1/2, JNK, MMP-2/9 in breast cancer; inhibits adenovirus and protects cardiovascular, immune, digestive, nervous systems.</p>

<p>JNK-IN-8 (JNK Inhibitor XVI) is an irreversible JNK1/2/4 inhibitor (IC50: 4.7/18.7/1 nM).</p>

<p>Epieriocalyxin A can suppress Caco-2 colon cancer cell growth. It could be a potential drug for colon cancer therapy in the future.</p>

<p>1.</p>

<p>IQ3 inhibits JNK3 (Kd 66 nM), JNK1/2, NF-κB/AP1 in THP1-Blue cells (IC50 1.4 μM), and reduces TNF-α/IL-6 production.</p>

<p>Indirubin-3′-oxime is an effective inhibitor of cyclin-dependent protein kinases, and may play an obligate role in neuronal apoptosis in Alzheimer's disease.</p>

<p>IQ-1S free acid (IQ-1S) is an effective and specific c-Jun N-Terminal Kinase Inhibitor. IQ-1S inhibits murine delayed-type hypersensitivity.</p>

<p>Sodium taurochenodeoxycholate: induces apoptosis, anti-inflammatory, boosts insulin, stimulates α2-cells, increases [Ca(2+)](c).</p>

<p>Fasudil hydrochloride (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK with Ki of 0.33 μM, 1.0 μM, 9.3 μM and 55 μM, respectively.</p>

<p>CC-90001 is an orally administered c-Jun N-terminal kinase (JNK) inhibitor with bias for JNK1 over JNK2.</p>

<p>Phytolaccaceae has anti-tumor activity, the mechanism may be related to the capacity of Esculentoside H for TNF release.</p>

<p>TCS JNK 5a (SC202671) is an effective, specific inhibitor of JNK3(pIC50= 6.7), JNK2(pIC50=6.5).</p>

<p>Ginsenoside Re (Ginsenoside B2) may have properties that inhibit or prevent the growth of tumors.</p>

<p>Juglanin is a JNK activator. Juglanin with inflammation and anti-tumor activities. It can induce apoptosis and autophagy on human breast cancer cells.</p>

<p>Tomatidine serves as an anti-inflammatory agent by inhibiting NF-κB and JNK signaling pathways.</p>

<p>Sesamolin and sesamin guard nerves, reduce microglia damage by blocking p38 MAPK and caspase-3, and curb nitric oxide in stimulated cells.</p>

<p>Pamapimod (R1503) (R-1503, Ro4402257) is a novel, selective inhibitor of p38 mitogen-activated protein kinase.</p>

<p>GSK649A is a novel activator of Satellite Cell Proliferation, it could enhance repair of Damaged Muscle.</p>

<p>SX 011 is a p38α inhibitor.</p>

<p>JNK-1-IN-1 is an inhibitor specifically targeting JNK-1, also exhibiting inhibition of MKK7 with an IC50 value of 7.8μM.</p>

<p>JNK3 inhibitor, potent and selective</p>

<p>TOPK-p38/JNK-IN-1 (Compound B12) is an orally active inhibitor of the TOPK-p38/JNK signaling pathway, with an IC50 value of 2.14 μM for the inhibition of NO</p>

<p>SR-3306 is a brain-penetrant and selective pan-JNK (JNK1/2/3) inhibitor with IC50 values ​​of 67 nM, 283 nM, 159 nM.Cost-effective and quality-assured.</p>

<p>BSJ-04-122: MKK4/7 inhibitor with IC50s of 4 nM &amp; 181 nM, used in cancer research.</p>

<p>SR-3737 is potent both JNK3 and p38 inhibitor.</p>

<p>J30-8 is a JNK3 inhibitor (IC50: 40 nM) with neuroprotective activity and can be used to study neurodegenerative diseases such as Alzheimer's disease.</p>

<p>JNK3 inhibitor-4: potent, selective JNK3 blocker (IC50=1.0nM), neuroprotective, BBB-permeable.</p>

<p>JNK-IN-11 inhibits JNK1/2/3 (IC50: 2.2/21.4/1.8 μM); promising for Alzheimer's/Parkinson's research.</p>

<p>JNK3 inhibitor-1: potent, selective, IC50 of 0.005 μM, orally bioavailable, brain-penetrant.</p>

<p>Ezatiostat HCl (TLK199) inhibits glutathione S-transferase, GSTP1-1 specifically, and may treat cytopenias.</p>

<p>TC ASK 10 is a potent, selective and orally active inhibitor of apoptosis signal-regulating kinase 1 (ASK1,IC50 = 14 nM). The IC50 value for ASK2 is 0.51 μM.</p>

<p>JNK3 Inhibitor-3 selectively blocks JNK3 (&gt;4.1 nM), crosses the blood-brain barrier, is orally active, and improves memory in dementia mice.</p>

<p>(±)-Perillaldehyde exhibits antidepressant effects in mice with stress-induced depressive-like behavior by modulating the olfactory nervous system. Additionally, it demonstrates anti-inflammatory activity by activating JNK in RAW264.7 cells and suppressing the expression of TNF-α, with an IC50 value of 171.7 μM.</p>

<p>JD118 is an inhibitor of JNK. It effectively suppresses the activity of JNK1 and the expression of cJun (1 - 135).</p>

<p>JNK-1-IN-5 (Compound 14) is a potent JNK1 inhibitor with sub-nanomolar efficacy. It effectively inhibits TGF-β-induced epithelial-mesenchymal transition and shows promise for research targeting JNK1 as an anti-pulmonary fibrosis agent.</p>

<p>p38 Kinase inhibitor 8 (Compound CCLXXVIII) is an orally active inhibitor targeting p38β and JNK2α2, with IC50 values of 6.3 nM and 53.6 nM, respectively. It has demonstrated anti-inflammatory effects in a rat model of collagen-induced arthritis.</p>

PT109 is a multikinase inhibitor that targets JNK and other kinases, playing a crucial role in anti-inflammatory, antioxidative, neurogenic, and synaptogenic processes. Specifically, PT109 inhibits JNK isoforms with the following IC50 values: JNK1 at 0.143 μM, JNK2 at 0.831 μM, and JNK3 at 0.285 μM. It also inhibits SGK isoforms (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM) and ROCK2 (IC50=34 μM). Additionally, PT109 reprograms polymorphic glioblastoma multiforme (GBM) into oligodendroglia via the PTBP1/PKM1/2 pathway and alters the metabolic pattern of GBM to exhibit antiglioma activity.

<p>JD123 inhibits the activity of JNK1 and the expression of cJun (1-135). It is an ATP-competitive inhibitor specific to p38-γ MAPK and has no effect on ERK1, ERK2, p38-α, p38-β, and p38-δ.</p>

<p>TLR4/JNK/NF-κB-IN-1 (Racemic-11k) is an inhibitor of TLR4, JNK, and NF-κB. It suppresses NO production in LPS-stimulated RAW264.7 cells with an IC50 of 23.2 µM. By inhibiting TLR4 expression and reducing JNK phosphorylation, TLR4/JNK/NF-κB-IN-1 prevents NF-κB activation. This leads to a decrease in the transcription of inflammation-related genes, reducing the expression of iNOS and COX-2, and the production of inflammatory mediators such as NO, PGE2, and TNF-α, thereby exhibiting anti-inflammatory activity. TLR4/JNK/NF-κB-IN-1 holds potential in the study of inflammatory diseases, including rheumatoid arthritis and various other inflammatory conditions.</p>

<p>JNK-IN-19 (Compound Q8) is an inhibitor of c-Jun N-terminal kinase, utilized for the treatment and/or prevention of injuries prior to, during, or following surgery.</p>

<p>JNK-IN-21 (Compound 62) is an inhibitor of JNK-1.</p>

<p>JAK3-IN-13: Oral JAK3 inhibitor, selective &amp; potent. Acts on NK1, JNK2, JNK3, Tyk2. Anti-tumor. IC50: JNK3, 8 nM; Tyk2, 365 nM; JNK2, 2039 nM; NK1, 4728 nM.</p>

<p>JNK-1-IN-4 (Compound E1) is an inhibitor of JNK, targeting JNK-1, JNK-2, and JNK-3 with IC50 values of 2.7, 19.0, and 9.0 nM, respectively. This compound inhibits the phosphorylation of c-Jun and reduces the expression of TGF-β1-induced EMT markers (such as fibronectin and α-SMA). JNK-1-IN-4 exhibits favorable pharmacokinetic properties with a bioavailability of 69%. Additionally, it demonstrates antifibrotic effects in a Bleomycin-induced mouse model of idiopathic pulmonary fibrosis.</p>